| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Entera Bio (NASDAQ:ENTX) reported its Q1 earnings results on Friday, May 5, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
Entera Bio beat estimated earnings by 33.33%, reporting an EPS of $-0.08 versus an estimate of $-0.12.
Revenue was down $68 thousand from the same period last year.
Last quarter the company beat on EPS by $0.01 which was followed by a 4.92% drop in the share price the next day.
Here's a look at Entera Bio's past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.11 | -0.13 | -0.16 | -0.18 |
| EPS Actual | -0.10 | -0.11 | -0.11 | -0.13 |
| Revenue Estimate | 50K | 90K | 70K | 180K |
| Revenue Actual | 14K | 8K | 44K | 68K |
To track all earnings releases for Entera Bio visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ENTX
